Clover Health

UBS raised its price target on Clover Health to $4.75 from $2.75 while keeping a Neutral rating, citing improved confidence in the company's operating outlook and profitability initiatives. Canaccord also lifted its target to $4.20 and reiterated a Buy rating after strong operating performance in April and May. Analysts point to a favorable managed-care environment and projected five-year EPS growth of 51.31% as drivers of growing optimism for Clover Health. » More on finance.yahoo.com

On May 18, 2026 Dr. Carladenise Armbrister Edwards reported a direct open-market sale of 67,160 Clover Health Investments shares for about $230,000 at a weighted average price of $3.42, reducing her direct holdings by 19.05% to 285,432 shares. The sale occurred after strong Q1 results but before the stock later climbed to a 52-week high of $5.49 following a favorable court ruling that could unlock additional Medicare revenue. Edwards' remaining sizeable stake and absence of further sales suggest she maintains confidence in the company's outlook. » More on finance.yahoo.com

Clover Health, a technology-powered provider of Medicare Advantage plans, raised its revenue forecast for the year to $2.81–$2.92 billion after strong results. Its core software, Clover Assistant, delivers real-time, AI-based recommendations to physicians, improving diagnoses and reducing treatment costs. The outlook and the AI features drove a sharp jump in the stock on June 10. » More on finanzen.net

Following a final court ruling, CMS recalculated Clover Health’s 2026 Medicare star rating from 3.5 to 4.5 stars, affecting PPO contract H5141 and influencing reimbursement rates and eligibility for quality bonus payments in 2027. The May 29, 2026 decision by the U.S. District Court for the Southern District of Georgia forced the recalculation; CMS informed Clover on June 9 about the upgrade. The news drove the stock up about 13% to a 52-week high of $5.01, supported by a recently reported GAAP profit and sharply higher revenues, despite broader market pressure from higher inflation. » More on de.investing.com

Clover Health's stock rose to a 52-week high of $3.92, gaining 52.77% year-to-date and 44.18% over six months. With a market capitalization of $2.06 billion and revenue growth of 48.69%, the company shows strong momentum. In Q1 2026 Clover Health beat revenue with $749.2 million but missed EPS at $0.05 versus an expected $0.07; an analysis by InvestingPro suggests the stock may be overvalued at current levels. » More on de.investing.com